General Information of Drug (ID: DMIQ263)

Drug Name
PMID29053063-Compound-7f Drug Info
Cross-matching ID
TTD Drug ID
DMIQ263

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Monoglyceride lipase (MAGL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABX-1431 DM9SYVJ Neuropathic pain 8E43.0 Phase 1 [2]
PMID29053063-Compound-11d DMDRK68 N. A. N. A. Patented [1]
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [1]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [1]
Pyrazole derivative 82 DMETCI3 N. A. N. A. Patented [1]
Pyrazole derivative 81 DMWT437 N. A. N. A. Patented [1]
PMID29053063-Compound-15 DM07U5R N. A. N. A. Patented [1]
Pyrazole derivative 80 DMQ3TGM N. A. N. A. Patented [1]
Carbamide derivative 24 DMD6Y73 N. A. N. A. Patented [1]
Piperazine carbamic compound 4 DMKZUO4 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoglyceride lipase (MAGL) TTZ963I MGLL_HUMAN Inhibitor [1]

References

1 A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)